Publicacións en colaboración con investigadores/as de Hospital Universitario de la Princesa (27)

2024

  1. Thrombosis with thrombocytopenia syndrome following adenovirus vector-based vaccines to prevent COVID-19: Epidemiology and clinical presentation in Spain

    Neurologia, Vol. 39, Núm. 9, pp. 721-732

2023

  1. Safety and Efficacy of ApTOLL in Patients with Ischemic Stroke Undergoing Endovascular Treatment: A Phase 1/2 Randomized Clinical Trial

    JAMA Neurology, Vol. 80, Núm. 8, pp. 779-788

2022

  1. Dyslipidemias and stroke prevention: recommendations of the Study Group of Cerebrovascular Diseases of the Spanish Society of Neurology

    Neurologia, Vol. 37, Núm. 1, pp. 61-72

2021

  1. Recommendations of the Spanish Society of Neurology for the prevention of stroke. Interventions on lifestyle and air pollution

    Neurologia, Vol. 36, Núm. 5, pp. 377-387

  2. Stroke prevention in patients with arterial hypertension: Recommendations of the Spanish Society of Neurology's Stroke Study Group

    Neurologia, Vol. 36, Núm. 6, pp. 462-471

  3. Stroke prevention in patients with type 2 diabetes or prediabetes. Recommendations from the Cerebrovascular Diseases Study Group, Spanish Society of Neurology

    Neurologia, Vol. 36, Núm. 4, pp. 305-323

  4. Time Trends in Intracerebral Hemorrhage Associated with Oral Anticoagulation and Its Risks Factors in Spain from 2008 to 2015

    European Neurology, Vol. 84, Núm. 1, pp. 16-21

2019

  1. The neurologist's approach to cerebral infarct and transient ischaemic attack in patients receiving anticoagulant treatment for non-valvular atrial fibrillation: ANITA-FA study

    European Journal of Neurology, Vol. 26, Núm. 2, pp. 230-237

2018

  1. Factors associated with poor anticoagulation control with vitamin K antagonists among outpatients attended in Internal Medicine and Neurology. The ALADIN study

    Revista Clinica Espanola, Vol. 218, Núm. 7, pp. 327-335

2017

  1. Clinical profile and satisfaction with anticoagulated treatment in patients with non-valvular atrial fibrillation attended in internal medicine and neurology departments of Spain

    Revista de Neurologia, Vol. 65, Núm. 8, pp. 361-367

2014

  1. Clinical management guidelines for subarachnoid haemorrhage. Diagnosis and treatment

    Neurologia

  2. Oct-2 transcription factor binding activity and expression up-regulation in rat cerebral ischaemia is associated with a diminution of neuronal damage in vitro

    NeuroMolecular Medicine, Vol. 16, Núm. 2, pp. 332-349

  3. The high-mobility group I-Y transcription factor is involved in cerebral ischemia and modulates the expression of angiogenic proteins

    Neuroscience, Vol. 269, pp. 112-130

2011

  1. Early biomarkers of clinical-diffusion mismatch in acute ischemic stroke

    Stroke, Vol. 42, Núm. 10, pp. 2813-2818

2008

  1. Biological signatures of brain damage associated with high serum ferritin levels in patients with acute ischemic stroke and thrombolytic treatment

    Disease Markers, Vol. 25, Núm. 3, pp. 181-188

  2. Body temperature and response to thrombolytic therapy in acute ischaemic stroke

    European Journal of Neurology, Vol. 15, Núm. 12, pp. 1384-1389

  3. High serum levels of endothelin-1 predict severe cerebral edema in patients with acute ischemic stroke treated with t-PA

    Stroke, Vol. 39, Núm. 7, pp. 2006-2010

  4. Marcadores moleculares asociados a signos precoces de isquemia en tomografía computarizada cerebral

    Neurologia, Vol. 23, Núm. 4, pp. 220-225

2007

  1. Increased body iron stores are associated with poor outcome after thrombolytic treatment in acute stroke

    Stroke, Vol. 38, Núm. 1, pp. 90-95

  2. Serum cellular fibronectin and matrix metalloproteinase-9 as screening biomarkers for the prediction of parenchymal hematoma after thrombolytic therapy in acute ischemic stroke: A multicenter confirmatory study

    Stroke, Vol. 38, Núm. 6, pp. 1855-1859